These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2771070)

  • 1. Effect of age at onset on progression and mortality in Parkinson's disease.
    Diamond SG; Markham CH; Hoehn MM; McDowell FH; Muenter MD
    Neurology; 1989 Sep; 39(9):1187-90. PubMed ID: 2771070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and levodopa. A five-year follow-up and review.
    Markham CH; Treciokas LJ; Diamond SG
    West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887
    [No Abstract]   [Full Text] [Related]  

  • 4. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.
    Lees AJ; Shaw KM; Stern GM
    Lancet; 1977 Nov; 2(8046):1034. PubMed ID: 72935
    [No Abstract]   [Full Text] [Related]  

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease.
    Kostic V; Przedborski S; Flaster E; Sternic N
    Neurology; 1991 Feb; 41(2 ( Pt 1)):202-5. PubMed ID: 1992362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease in Taiwan: an analysis of 215 patients.
    Chia LG; Liu LH
    Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: progression and mortality.
    Hoehn MM
    Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-center study of Parkinson mortality with early versus later dopa treatment.
    Diamond SG; Markham CH; Hoehn MM; McDowell FH; Muenter MD
    Ann Neurol; 1987 Jul; 22(1):8-12. PubMed ID: 3631925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinsonism treated with levodopa: progression and mortality.
    Maier Hoehn MM
    J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does ageing aggravate parkinsonian disability?
    Blin J; Dubois B; Bonnet AM; Vidailhet M; Brandabur M; Agid Y
    J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):780-2. PubMed ID: 1955894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 16. Nosography of Parkinson's disease.
    Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1986; 22():119-28. PubMed ID: 3465866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of male-female differences in progression and mortality of Parkinson's disease.
    Diamond SG; Markham CH; Hoehn MM; McDowell FH; Muenter MD
    Neurology; 1990 May; 40(5):763-6. PubMed ID: 2330103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing epidemiology of Parkinson's disease: predicted effects of levodopa treatment.
    Marttila RJ; Rinne UK
    Acta Neurol Scand; 1979 Mar; 59(2-3):80-7. PubMed ID: 452843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.
    Wagner ML; Fedak MN; Sage JI; Mark MH
    Ann Clin Lab Sci; 1996; 26(5):389-95. PubMed ID: 8879356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.